Emmaus Life Sciences today announced the submission of its application for marketing authorization of Endari® to the United Arab Emirates (U.A.E.) Ministry of Health.
Read MoreAgreement Expands on the Companies’ Collaboration for the Preclinical Development of Potential Anti-Cancer Therapies
Read MoreOTC Markets Group Inc. (OTCQX: OTCM) today announced Emmaus Life Sciences, Inc. (OTCQX: EMMA) has qualified to trade on the OTCQX® Best Market. Emmaus Life Sciences, Inc. upgraded to OTCQX from the Pink® market.
Read MoreEmmaus Life Sciences, Inc. (OTC: EMMA) announced financial results for the six months ended June 30, 2021. As a result, the company is now current in its Securities and Exchange Commission (SEC) reporting obligations.
Read MoreLicense Permits Importation and Early Access to Patients Pending Marketing Authorization
Read More